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Abstract
TCTP has been implicated in a plethora of important cellular processes related to cell growth, cell cycle progression,
malignant transformation and inhibition of apoptosis. In addition to these intracellular functions, TCTP has extracellular
functions and plays an important role in immune cells. TCTP expression was previously shown to be deregulated in prostate
cancer, but its function in prostate cancer cells is largely unknown. Here we show that TCTP expression is regulated by
androgens in LNCaP prostate cancer cells in vitro as well as human prostate cancer xenografts in vivo. Knockdown of TCTP
reduced colony formation and increased apoptosis in LNCaP cells, implicating it as an important factor for prostate cancer
cell growth. Global gene expression profiling in TCTP knockdown LNCaP cells showed that several interferon regulated
genes are regulated by TCTP, suggesting that it may have a role in regulating immune function in prostate cancer. In
addition, recombinant TCTP treatment increased colony formation in LNCaP cells suggesting that secreted TCTP may
function as a proliferative factor in prostate cancer. These results suggest that TCTP may have a role in prostate cancer
development.
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Introduction
Prostate cancer is the most frequently diagnosed non-cutaneous
malignancy and the third leading cause of cancer-related deaths in
men in western industrialized countries [1]. The importance of
androgens for the development and progression of prostate cancer
was shown early in the 20th century. This resulted in significant
focus on androgens and the receptor to which they bind, the
androgen receptor (AR) [2], and androgen ablation therapy
became the main line of therapy. Even though AR and androgen
action are critically important aspects in prostate cancer, it has
become evident that other signaling pathways, as well as non-
genomic and genomic alterations, are involved in the development
and progression of prostate cancer (reviewed in [3]).
Translationally controlled tumor protein (TCTP) is a multifac-
eted factor which is highly conserved in a number of species. It was
originally discovered in a mouse sarcoma cell line as a protein
regulated at the translational level [4]. TCTP has since been
implicated in a number of important cellular processes, such as cell
growth, malignant transformation and inhibition of apoptosis.
TCTP is not found exclusively in tumor cells, but has a widespread
expression profile that is not restricted to a specific tissue or cell
type. However, TCTP expression is generally higher in tumors
compared to corresponding normal tissue (reviewed in [5]).
TCTP has an anti-apoptotic role in a number of cell lines
(reviewed in [6]). TCTP knockout mice are embryonically lethal
with reduced number of cells and a higher incidence of apoptosis
in the embryos, highlighting its importance in early development
[7,8]. In addition, TCTP has been shown to bind calcium [9–12];
this property may be linked to its anti-apoptotic activity as the
concentration of free intracellular calcium is known to increase
during apoptosis, triggering a sequence of events leading to cell
death [13]. TCTP is engaged in a variety of protein-protein
interactions and binds tubulin, Plk-1, p53 and the guanine
nucleotide exchange factor Rheb, amongst others [14]. In
addition, TCTP mRNA is highly structured and activates PKR,
a protein kinase involved in the inflammatory response [15].
Although these studies offer plausible explanations for the many
reported effects of TCTP, the exact mechanisms by which TCTP
functions remain to be delineated.
TCTP is also a secreted protein with extracellular functions
[16]. The secreted form of TCTP was originally identified by its
ability to promote histamine release from basophils in a subset of
allergic donors and thus named Histamine Releasing Factor
(HRF) [17]. Additionally, TCTP stimulated B-cell proliferation,
induced expression of IL-1, IL-6, and immunoglobulin production
consistent with a role as a B-cell growth factor [16]. TCTP does
not contain an N-terminal signal sequence typical for secreted
proteins and is secreted through a non-classical pathway involving
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exosomes [18]. Interestingly, nanovesicles secreted from apoptotic
endothelial cells that act in a paracrine fashion contain TCTP,
further extending the modality of its extracellular action [19].
Recent studies have identified TCTP expression in the human
prostate. TCTP was found to be expressed in prostatic tissues from
men undergoing surgical adenomectomy for benign prostatic
hyperplasia (BPH) and in cell lines derived from normal prostate,
such as the cell line PWR-1E, and prostate cancer [12]. TCTP
expression was also found to be higher than other calcium binding
proteins (CBPs) in the human prostate. In addition, immunohis-
tochemical analyses of normal prostate indicated that TCTP was
mainly expressed by the secretory luminal cells and to a smaller
degree by the basal cells. TCTP was also identified in prostatic
fluids, which suggests that it may have an extracellular role in the
prostate [12]. In addition, TCTP may affect proliferation and
viability in prostate cancer cells [20]. LNCaP cells treated with
siRNA targeting TCTP indicated that knockdown of TCTP
increases apoptosis through caspase 3 and caspase 8 and reduces
cell proliferation in LNCaP cells [20]. Furthermore, results from a
recent study indicate that heat shock protein 27 (Hsp27) interacts
with TCTP in prostate cancer cells and protects it from
degradation [21]. In addition, TCTP expression levels correlated
with disease progression, where it was upregulated in castration
resistant prostate cancer (CRPC) [21]. These studies implicate
TCTP in prostate cancer; however, there is limited information on
its regulation and function in prostate cancer cells.
Here we show that TCTP is regulated by androgens, important
survival factors for prostate cancer cells as well as the normal
prostate. Ectopic expression of TCTP and its knockdown, as well
as experiments with recombinant TCTP, show that it contributes
to cell growth and proliferation, implicating it as an important
factor in prostate cancer.
Materials and Methods
Ethics Statement
This study was approved by the Regional Ethics Committee,
REK Sør-Øst (S-07443a), and material from still living patients
was included after their written consent. Use of material from dead
patients was permitted by the Ethics Committee. Animal
experiments were approved by Case Western Reserve University
IACUC guidelines. All steps taken for animal welfare and to
Figure 1. Androgen induces TCTP expression in vitro and in vivo. A. LNCaP cells were either left untreated or treated with the synthetic
androgen R1881 (1028 M) for the indicated times. Total RNA was isolated and qPCR analyses were performed. TCTPmRNA expression was normalized
to GAPDH. The graph illustrates one representative experiment performed in triplicate with error bars indicating 6SEM, the expression levels are
relative to cells treated without androgen (set to 1). The experiment was repeated more than three times B. Western analyses were performed on
whole cell extracts made from cells treated in the absence or presence of R1881 (1028 M) for the indicated time points. The expression levels were
normalized to GAPDH. The values presented are relative to untreated samples (set to 1). The graph illustrates data from two experiments performed
in triplicate with error bars illustrating 6SEM. C. CWR22 xenografts were grown in nude mice and tumor samples were collected either before (t = 0)
or 1, 2 and 4 weeks after castration. Total cell extracts were made and used for western blot analyses. The figure shows one representative blot for
TCTP and GAPDH, with relative values of TCTP (t = 0 set to 1) normalized to GAPDH. The differences between the groups were evaluated using two-
tailed, paired Student’s t-test compared to non-treated samples, with P,0.05 being considered as significant. Significance is indicated by asterisks;
one asterisk indicates P,0.05, two asterisks indicate P,0.01.
doi:10.1371/journal.pone.0069398.g001
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minimize suffering were according to IACUC guidelines and have
previously been described [22,23].
Cell Culture
LNCaP cells were obtained from the American Type Culture
Collection (ATCC) and cultured in RPMI 1640 medium
supplemented with 10% Fetal Calf Serum (FCS), 2 mM L-
glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin
(Lonza). The human bronchial epithelial BEAS-2B cell line
transformed with SV40 was a generous gift from Sten Mollerup
(Department of Toxicology, National Institute of Occupational
Health, Oslo, Norway) [24]. BEAS-2B cells were maintained in
LHC-9 medium supplemented with 1.8 mg/ml bovine serum
albumin (BSA) on plates coated with 0.01 mg/ml fibronectin and
0.03 mg/ml bovine collagen dissolved in PBS.
For both cell lines the culture media was changed every two to
three days, and the cells were incubated at 37uC in a humidified
5% CO2, 95% air incubator. For androgen induction experi-
ments, LNCaP cells were starved for 48 h in RPMI 1640
containing 2% charcoal treated (CT)-FCS, followed by an
additional 24 h in RPMI 1640 containing 0.5% CT-FCS prior
to treatment with 1028 M R1881 (synthetic androgen). R1881 was
obtained from NEN.
Xenograft Experiments
Transplantation, growth, and harvest of tumors from mice
bearing CWR22 xenografts were as described previously [22,23].
CWR22 xenografts were grown in nude mice in the presence of a
sustained-release testosterone pellet. After tumor growth, mice
were castrated, the testosterone pellets were removed and the
regressing tumors were collected at 1, 2, or 4 weeks after
castration. Animals were housed and treated according to the
IACUC guidelines.
Quantitative PCR (qPCR)
Upon harvest, total RNA was extracted from cells using TrizolH
reagent (Invitrogen) according to manufacturer’s recommenda-
tions. 1–5 mg RNA was used for first-strand cDNA synthesis with
the SuperScript II system (Invitrogen) and oligo-dT primers.
qPCR analyses were performed on the LightCycler 480
Figure 2. TCTP knockdown reduces colony formation of LNCaP cells. A. siRNA mediated knockdown of TCTP in LNCaP cells. LNCaP cells
were transfected with siRNA (100 nM) targeting either Luciferase (Luc) or TCTP. At the indicated time points cells were harvested, protein extracts
were prepared and analyzed by western analysis. Antisera raised against TCTP and GAPDH were used sequentially on the same blot. B. LNCaP cells
were transfected with 100 nM siRNA targeting Luc or TCTP, seeded in 10 cm plates and assayed for colony formation ability by crystal violet staining
after three weeks of growth. Representative pictures are shown. C. Quantification of colony formation of LNCaP cells after siRNA mediated
knockdown of TCTP. The graph represents two experiments in triplicate. The differences between the groups were evaluated using two-tailed, paired
Student’s t-test compared to Luc-siRNA treated samples, with *: P,0.05 indicating significant difference.
doi:10.1371/journal.pone.0069398.g002
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instrument (Roche) with the LightCycler 480 SYBR Green I
Master mix (Roche). A standard curve made from serial dilutions
of cDNA was made to calculate the relative amount of the target
and reference gene for each sample. These values were then
normalized to the relative amount of the reference gene. Primers
are available upon request. The differences between the groups
were evaluated using a two-tailed, paired Student’s t-test, with
P,0.05 being considered as significant.
Protein Extraction and Western Analyses
Whole cell extracts were made as previously described [25],
resolved by SDS-PAGE and transferred to a PVDF membrane
(Bio-Rad). The blotted membrane was blocked in 10% nonfat dry
milk in Tris-buffered saline (TBS) containing 0.1% Tween (TBS-
Tween) for 1 h followed by incubation with primary antibody in
TBS-Tween containing 5% bovine serum albumin (BSA) for 14–
16 h at 4uC. Antibodies against either TCTP (1:1000) [12], or
GAPDH (1:500) (Santa Cruz) were used. Enhanced Chemilumi-
nescence Western blotting detection reagents (Amersham Biosci-
ences) and analysis system were utilized for the detection of the
HRP labelled proteins. For quantification, western blots were
digitalized with a scanner machine (Epson Perfection V700 Photo)
and the optical density was measured with the software
ImageQuant TL (Amersham Biosciences). Human TCTP mouse
monoclonal antibody was a generous gift from the group of del
Vecchio [12].
RNA Interference
Synthetic siRNA targeting TCTP (target sequence 59- AAC-
CATCACCTGCAGGAAACA-39) was obtained from Dharma-
con, while siRNA for luciferase (target sequence: 59-AACT-
TACGCTGAGTACTTCGA-39) was from Qiagen. LNCaP cells
were seeded in full medium 24 h before transfection. The medium
was changed to RPMI 1640 without FCS and antibiotics prior to
transfection, and the cells were transfected with 100 nM siRNA
per well using Oligofectamine (Invitrogen) according to the
manufacturer’s protocol.
Colony Formation Assay
LNCaP cells were transfected with siRNA as described above
and plated in 10 cm plates at a density of-100000 cells/well.
Colonies were grown for three weeks. LNCaP cells treated with
recombinant TCTP were seeded at a density of 2500 cells per well
in a six-well plate in RPMI supplemented with 10% FCS.
Figure 3. Downregulation of TCTP expression leads to increased apoptosis in LNCaP cells. LNCaP cells were cultured on coverslips and
transfected with siRNA against TCTP or Luciferase (Luc) for 72 h. Apoptosis was induced by 100 nM TG for 36 h during siRNA treatment. After
treatment and fixation, apoptotic cell death was detected using the TUNEL assay, cell nuclei were stained with DAPI and cells were visualized using
Axioplan imaging microscope. A. Representative pictures of LNCaP cells transfected with either TCTP- or Luc-siRNA for 72 h and treated with DSMO
or TG for 36 h during transfection. TUNEL positive cells appear as red spots. Arrows indicate apoptotic cells. B. Quantification of apoptosis incidence.
The data show the percentage of nonviable cells after 36 h treatment with TG in cells transfected with TCTP or Luc siRNA. Columns represent the
mean of three independent experiments performed in triplicate and bars represent 6SEM with *: P,0.05 indicating significant difference.
doi:10.1371/journal.pone.0069398.g003
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Recombinant TCTP, GST, or vehicle control was added every
two to three days. Colony formation was assessed after two weeks
of growth. Cells were fixed in methanol at 220uC for 30 min,
stained with 0.1% crystal violet for 20 min and then washed with
MQ water. The area covered by the colonies was quantified using
GeneTools software from SynGene.
TUNEL Assay
LNCaP cells were seeded on cover-slips, starved and transfected
with siRNA as described above. For thapsigargin (TG) induction,
the cells were either treated with vehicle or 100 nM TG for the last
36 h of the 72 h transfection period. To detect apoptosis, a
TUNEL In Situ Cell Death Detection Kit (Roche) was used
according to the manufacturer’s instructions. Fluorescence was
detected using an Axioplan2 imaging microscope (Zeiss) and
pictures were taken with an AxioCam HRc camera (Zeiss). The
number of TUNEL-positive cells was expressed as a percentage of
the total number of cells.
Gene Expression Profiling
Total RNA from cells treated with siRNA was isolated using the
TRIzolH reagent according to the manufacturer’s instructions and
was analyzed at the Norwegian Microarray Consortium (NMC),
Oslo University Hospital, Oslo, Norway. The RNA was amplified
using the IlluminaH TotalPrep RNA Amplification kit (Illumina).
500 ng total RNA was used in the amplification and labelling
reaction. The quality of the cRNA was assessed using a
Bioanalyser. Biotin labelled cRNA (1.5 mg) was then used to
hybridize onto Illumina Human-6 v3 Expression beadchips using
the Whole-Genome gene Expression Direct Hybridization assay
from Illumina. After scanning, the results were imported into
Illumina BeadStudio, where the quality of each array and scan
were tested.
Generation of and Treatment with Recombinant TCTP
The open reading frame (ORF) of hTCTP was cloned into
pET-28a for expression of recombinant TCTP. 0.1 mM IPTG
was used to induce expression, and following harvest the pellet was
resuspended in binding buffer (20 mM NaH2PO4, 500 mM NaCl,
20 mM imidazol, pH 7.4). Protease inhibitors were added and the
cell suspension was sonicated at 4uC. His-tagged hTCTP was
purified under native conditions using a HiTrapTM Chelating HP
Column (GE Healthcare) charged with Ni2+-ions according to the
manufacturer’s instructions. The sample was sterile filtered and
diluted with binding buffer prior to application onto the column.
The column was washed with binding buffer until the absorbance
(280 nm) stabilized. Bound proteins were then eluted with elution
buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazol,
Figure 4. TCTP knockdown increases interferon induced gene expression. LNCaP cells were transfected with siRNA against TCTP or
Luciferase for 72 h, RNA was isolated and used in global gene expression profiling as described in Materials and Methods. A. Venn diagram of the
genes that are significantly regulated by gene expression profiling. B. Heatmap representation of genes up- or down-regulated in response to TCTP
knockdown. Red and green represent up- and downregulated genes, respectively. C. List of the ten most significantly regulated genes with their
accession numbers, definition and the ontology process for which they are implicated in. The fold change relative to Luciferase siRNA treated cells are
indicated.
doi:10.1371/journal.pone.0069398.g004
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pH 7.4). The purification procedure was performed at 4uC to
prevent protein degradation. The eluate was dialyzed against PBS
using Slide-A-LyzerH 10K dialysis cassettes with a cut-off value of
10 kDa. To obtain recombinant GST, pGEX-4T was grown in
BL21 cells, induced with 0.1 mM IPTG and purified by
incubation with 50% Glutathione Sepharose 4B slurry. The beads
were washed with PBS before elution (50 mM Tris-HCl, 10 mM
reduced glutathione, pH 8.0). The purified proteins were run
alongside Precision Plus Dual color Protein Standard, Prestained
Protein Markers, Broad Range (7–175 kDa) and Unstained
Protein Markers, Broad Range (2–212 kDa) (Biorad) to estimate
the amount of protein.
BEAS-2B cells were treated with recombinant TCTP/GST for
one h before harvest.
Immunohistochemistry
Tissue microarrays (TMA) were prepared from radical
prostatectomy specimens from patients operated at the Norwe-
gian Radium Hospital between 1988 and 1996 and followed up
after surgery. Prostate-specific antigen (PSA) measurements were
performed before and after operation and at every subsequent
clinical examination. Follow-up periods ranged from 2 to 176
months (mean, 73.3 months). Patients were considered to have
clinically evident recurrence of disease if any of the following
were present: (a) evidence of local recurrence (confirmed by
histological biopsies or ultrasound) or (b) evidence of distant
metastasis (detected by skeletal scintigraphy and/or magnetic
resonance imaging). If a patient who suffered from relapse had
postoperative serum PSA of .4 ng/ml before the date of either
local recurrence or metastasis, the date of elevated PSA was set
as the relapse date. H&E-stained sections were made from each
selected primary tumor block (donor blocks) of paraffin-
embedded material to define representative tumor regions.
With the use of the tissue array instrument (Beecher Instru-
ments), two tissue cylinders (0.6 mm in diameter) were punched
from regions of the donor block. Control samples of non cancer
tissue from the paraffin blocks were also taken. The Gleason
score used in the analysis was the highest Gleason score in each
of the prostatectomy series.
The TMAs were first de-paraffinized by xylene and serial
ethanol dilutions and washed in H2O prior to quenching of
endogenous peroxidase in 0.3% H2O2 in H2O for 30 min.
Antigen retrieval was carried out by autoclaving at 121uC for
20 min in 0.01 M citrate buffer (pH 6.4). The BioGenex Super
Sensitive Link-Label IHC Detection kit (BioGenex) was used for
antigen detection. The sections were equilibrated in TBS-Tween
(0.05 M Tris, pH 7.5, 0.3 M NaCl, 0.1% Tween 20) for 5 min
prior to incubation overnight at 4uC with anti-human TCTP
Figure 5. Reduction of TCTP increases interferon induced gene expression. A–F. qPCR was used to assess expression of genes predicted to
be differentially expressed in cells tranfected with Luc-siRNA versus TCTP-siRNA. The mRNA expression was normalized to GAPDH and was calculated
relative to Luc-siRNA samples (set to 1). Experiments were carried out in triplicate. All error bars represent 6SEM. Statistical significance was assessed
using two-tailed, paired Student’s t-test with *: P,0.05 and **: P,0.01 being considered as significant.
doi:10.1371/journal.pone.0069398.g005
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mouse monoclonal antibody diluted 1:100 in TBS-Tween with
1% BSA. Sections were then washed with TBS-Tween prior to
incubation with biotinylated secondary anti-imouse IgG (link) for
30 min at room temperature. After wash in TBS-Tween, the
secondary antibody was incubated with enzyme HRP-labeled
streptavidin for 30 min at room temperature. The slides were then
washed in TBS-Tween and stained with DAB for 5 min and the
reactions were stopped in H2O. Counterstain was performed by
haematoxylin (DAKO) staining and the slides were mounted with
DAKO Faramount aqueous mounting medium. Mouse non-
immune serum was applied as negative control. Normal prostate
tissue sections were used as positive controls. Intensity was scored
using a 0–3 scale, corresponding to absent, weak, moderate, and
intense staining, respectively. The differences between the groups
were evaluated using a two-tailed, unpaired Student’s t-test, with
P,0.05 being considered as significant.
Statistics
Except for the microarray analyses, statistics were carried out
using Student’s t-test where p values ,0.05 were considered
significant.
Statistical analysis of gene expression data. Statistical
analysis was performed based on summary expression values for
each probe and normalized by quantile normalization which
results in the chips having identical intensity distribution. The data
were analyzed by J-Express v2.7 software (http://www.molmine.
com). Statistical Analysis of Microarrays (SAM) and Feature
Subset Selection (FSS) were used for statistical analyses.
Results
TCTP Expression is Induced by Androgens
We first investigated the possible regulation of TCTP expression
by androgens in the androgen responsive prostate cancer cell line
LNCaP in a time course experiment. As shown in Figures 1A and
Figure 6. Recombinant TCTP increases colony formation of LNCaP cells. A. BEAS-2B cells were treated with recombinant TCTP or GST (rTCTP
and rGST) to a final concentration of 1.0 mg/ml, total RNA was extracted, cDNA synthesized and qPCR performed. GAPDH was used as a reference
gene and the values presented are relative to GST (set to 1). B. Colony formation assay in LNCaP cells treated with rTCTP or rGST. Cells were cultured
in the presence of rTCTP or rGST at a final concentration of 1.0 mg/ml for two weeks and the colonies formed were visualized with 0.1% crystal violet.
The area covered on each plate by the colonies was measured and represented as percentage of the total area of the plate. C. Two representative
images are shown. The experiment was carried out in triplicate three times. Error bars represent 6SEM. Statistical significance was assessed using
two-tailed, paired Student’s t-test. Significance is indicated by asterisk, P,0.05.
doi:10.1371/journal.pone.0069398.g006
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1B, there was an androgen-induced increase in both TCTP
mRNA and protein accumulation over time, which reached
approximately four-fold higher levels compared with untreated
cells at 48 h. To determine if TCTP expression is also regulated by
androgens in vivo, we used the human androgen-dependent
prostate cancer xenograft model CWR22 which markedly
regresses after castration [22,23]. Western analysis of CWR22
tumors collected from mice at different time points after castration
showed that the TCTP expression significantly decreased in a
time-dependent manner and was nearly lost at four weeks
(Figure 1C). These results show that TCTP expression is regulated
by androgens in prostate cancer cells both in vitro and in vivo.
Knockdown of TCTP Decreases Colony Formation of
LNCaP Cells
Androgen regulation of TCTP expression, as presented above,
suggested that it may have a role in growth of prostate cancer cells.
This could either be through the induction of proliferation or
inhibition of apoptosis, or a combination of both. To investigate
the possible role of TCTP in cell growth, its expression was
inhibited in LNCaP cells by siRNA treatment and colony
formation was assessed compared with control siRNA treated
cells. As shown in Figure 2A, TCTP protein expression was
reduced by 85% after 72 h of transfection with siRNA targeting
TCTP. Colony formation of TCTP knockdown cells was
decreased by 50% compared with control cells (Figures 2B and
2C). These data indicated that TCTP may have a role in LNCaP
cell proliferation and/or viability.
Down-regulation of TCTP Increases Apoptosis of LNCaP
Cells
TCTP was previously reported to inhibit apoptosis in a number
of cell lines [20,26–28]. In addition, RNAi-mediated knockdown
of TCTP in LNCaP cells activated caspase 3 and caspase 8,
indicative of increased apoptosis [20,21]. We thus investigated the
possible role of TCTP on apoptosis in LNCaP cells. Previous work
from our laboratory has established that Thapsigargin (TG)
induces significant apoptosis after 36 h of treatment in LNCaP
cells [25]. We thus determined whether TCTP may alter TG-
induced apoptosis. LNCaP cells were transfected with either
siRNA against TCTP or control (Luciferase) siRNA, then left
untreated or exposed to TG, after which the extent of apoptosis
was determined using the TUNEL assay. As shown in Figures 3A
and 3B, in the absence of TG treatment, there was an
approximately three-fold increase in apoptosis in TCTP knock-
down cells compared with control cells. As expected, TG
significantly increased apoptosis in both control or TCTP-siRNA
treated cells, however, it was approximately 2.5-fold higher upon
TCTP knockdown. The knockdown of TCTP was verified by
qPCR for all experiments (data not shown). These data suggest
that TCTP is involved in regulating apoptosis in prostate cancer
cells.
Down-regulation of TCTP Results in Upregulation of
Immune Response Genes in LNCaP Cells
In order to elucidate the pathways TCTP may affect in prostate
cancer cells, we conducted a global gene expression profiling in
TCTP knockdown cells compared with control LNCaP cells.
Significant TCTP knockdown was confirmed at both mRNA and
Figure 7. TCTP expression is increased in prostate cancer compared to normal prostate. Tissue microarrays with normal and tumor tissue
from human prostate were stained with TCTP antiserum and detected by Biogenex Supersensitive Detection kit. The graph is based on 392 samples
consisting of 35 benign and 357 malignant samples. The differences between the groups were evaluated using two-tailed, unpaired Student’s t-test
compared to untreated samples, with P,0.05 being considered as significant. **: P,0.01.
doi:10.1371/journal.pone.0069398.g007
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protein level (data not shown). The data were analyzed using two
methods: the Statistical Analysis of Microarrays (SAM) and
Feature Subset selection (FSS) tools implemented in J-Express
[29]. Out of the 15 most significantly regulated genes determined
by each analysis, nine were found to be significant by both
methods, as illustrated in the Venn diagram in Figure 4A.
Figure 4B shows up- or down-regulation of some of the genes,
while a list over the most significantly regulated genes on the array,
their ontology, known function and definition are depicted in
Figure 4C. The majority of the genes predicted to be significantly
regulated upon TCTP knockdown are involved in the interferon
signaling pathway and/or immune-related responses. The expres-
sion of six of these genes (IFIT1, SLITRK3, IFI44L, IFIT3, OAS2
and MX1) was validated by qPCR (Figures 5A–F). These results
imply that TCTP modulates immune responses in prostate cancer
cells.
Recombinant TCTP Induces Prostate Cancer Cell Growth
The secreted form of TCTP has previously been shown to
induce expression of several mediators, initiate distinct signaling
events and lead to an increase in cell proliferation of immune cells
[30–32]. Since TCTP is present in prostatic fluids [12], it may
have an extracellular function in prostate cancer cells. To assess
this possibility, we made recombinant TCTP (rTCTP) in E. coli
and determined its biological activity in BEAS-2B cells compared
with recombinant glutathione S-transferase (rGST) as a control
[33]. BEAS-2B cells were treated with rTCTP or rGST at a final
concentration of 1.0 mg/ml for 1 h and IL-8 mRNA production
was determined by qPCR. IL-8 mRNA expression was signifi-
cantly increased in cells treated with rTCTP compared to cells
treated with rGST (Figure 6A) indicating that the rTCTP is
biologically active. LNCaP cells were then treated with 1.0 mg/ml
rTCTP or rGST and a colony formation assay was performed.
After two weeks in culture with continuous exposure to the
recombinant proteins, cells were fixed and stained to visualize
colonies. As shown in Figures 6B and 6C, there were a significantly
higher number of colonies formed by the cells treated with rTCTP
compared to rGST-treated cells. These data indicate that rTCTP
has a proliferative/pro-survival effect on LNCaP cells and suggest
a role of secreted TCTP in prostate cancer cell growth.
TCTP Expression is Upregulated in Prostate Cancer
Compared to Normal Prostate
Since TCTP is expressed in the normal prostate, as well as
regulated by androgens in prostate cancer cells in vitro and in vivo,
we investigated its expression on tissue microarrays (TMAs)
containing normal prostate tissue as well as those representing
various stages of prostate cancer using immunohistochemistry
(IHC). As shown in Figure 7A, TCTP was expressed primarily in
epithelial cells in both normal prostate and prostate cancer.
Furthermore, its expression was significantly increased in cancer
tissue compared with normal cells (Figure 7B), which indicates that
TCTP may have a role in prostate cancer.
Discussion
TCTP is a highly conserved protein in eukaryotes, from yeast to
mammals, and abundantly expressed in a wide range of tissues (for
a review, see 5). Several studies have underscored the multiple
processes TCTP is involved in, such as immune responses, cell
proliferation, tumorigenicity, and cell death [5]. The data
presented here establish TCTP as an androgen regulated gene
implicated in prostate cancer.
Androgen signalling and AR are critical for all phases of
prostate cancer [34]. We found that TCTP is a novel androgen
regulated gene whose expression is induced at both mRNA and
protein level by androgens (Figures 1A and 1B). Furthermore,
upon castration, the expression of TCTP dramatically declined in
CWR22 androgen dependent xenografts grown in nude mice,
indicating that its expression is regulated by androgens also in vivo
(Figure 1C). Since androgens increase proliferation and inhibit
apoptosis, which is the same outcome as observed in our
experiments by TCTP manipulation, it is tempting to speculate
that growth and viability regulating effects of androgens, at least in
part, may be mediated by TCTP.
TCTP depletion in LNCaP cells significantly increased both
basal levels of apoptosis, consistent with previous findings [20], as
well as TG- induced apoptosis (Figure 3). These findings are
consistent with a recent study that developed a TCTP antisense
oligonucleotide (ASO) which inhibited the growth of PC-3 and
LNCaP xenografts and significantly enhanced docetaxel activity
upon systemic delivery [21]. These data open up the possibility for
using TCTP knockdown in parallel with other established
therapeutic approaches to increase treatment efficacy.
Gene expression profiling data indicated that approximately
60% of the differentially regulated genes are involved in the
interferon (IFN) pathway (Figure 4). IFNs are a family of cytokines,
named for their ability to interfere with viral infection. They
mediate antiviral and antigrowth responses and are also known to
modulate adaptive immune responses [35]. These findings are
interesting given that TCTP was recently found to interact with
NEMO, an upstream adaptor protein in the NF-kB pathway, and
that NF-kB regulates transcription of inflammatory and survival
genes [36]. In pilot experiments we observed that the NF-kB
pathway is activated upon TCTP knockdown in LNCaP cells
consistent with the notion that TCTP regulates immune responses
in prostate cancer (data not shown). The IFN stimulated genes
have been implicated in several cancers, including prostate cancer;
however, what specific role they play in the different cancers and
at what disease stage are currently unknown [37–42]. Interesting-
ly, the IFN stimulated genes were not affected by androgen
induction in LNCaP cells (data now shown); this could mean that
TCTP may collaborate with other factors that are not regulated by
androgens. Alternatively, since androgen induction of TCTP takes
at least 48 h, longer time exposure to androgens may be needed to
observe any effects on IFN pathway related genes. Further work is
necessary for determining the possible consequence of IFN gene
expression changes on PCa cell growth and viability.
The secreted form of TCTP is well-studied in immune cells,
where it has been shown to function as a histamine releasing
factor, induce secretion of various interleukins, initiate distinct
signal transduction events, and affect cell proliferation (reviewed in
[16]). Since TCTP was earlier found in prostatic fluids [12], it was
suggested to have a role in prostate function and in prostate
cancer; however, there have not been any studies to date which
addressed the possible effect of rTCTP on prostate cancer cells.
Consistent with the other data presented herein, and the function
of TCTP in immune cells, we found that rTCTP increased colony
formation in LNCaP cells (Figure 6). This indicates that the
proliferative effects of secreted TCTP is not restricted to immune
cells and is also applicable to prostate cancer cells. rTCTP has
previously been implicated in the induction of distinct signal
transduction pathways in immune cells [30,32]; it is therefore of
interest to investigate whether this is also the case in prostate
cancer cells. Further studies elucidating the molecular mechanisms
behind these results are therefore warranted.
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TCTP was previously found to be expressed in normal prostate
and prostate cancer cells [12,21]; it was also found to be further
increased in castration resistant prostate cancer [21]. In line with
these findings, we found a significant increase in TCTP expression
in a TMA representing a collection of prostate cancer samples
from various cancer stages compared with benign prostate
(Figure 7). These data are consistent with earlier findings where
TCTP was suggested to be involved in the process of initiation and
progression of castration resistant prostate cancer [21].
Taken together, our data and earlier findings suggest that
TCTP expression is relevant for human prostate cancer. TCTP
may have a unique role in regulating inflammation and
carcinogenesis processes thought to be tightly linked, making it a
potential biomarker and a therapeutic target in prostate cancer.
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